FASLG (Fas Cell Surface Death Receptor Ligand) is a gene encoding the Fas ligand (FasL/CD95L), a Type II transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. FasL is a critical effector of apoptosis (programmed cell death) and plays a significant role in immune privilege, tumor immune evasion, and neuronal cell death in neurodegenerative diseases.
- Gene Symbol: FASLG
- Official Name: Fas ligand (TNF superfamily, member 6)
- Chromosomal Location: 1q24.3
- NCBI Gene ID: 3564
- Uniprot ID: P48023
¶ Protein Structure and Function
The Fas ligand protein is a Type II transmembrane protein with the following structural features:
- N-terminal intracellular domain: Contains a proline-rich region important for protein-protein interactions
- Transmembrane domain: Anchors the protein to the cell membrane
- C-terminal extracellular domain: The functional domain that binds to Fas receptors
FasL functions as a trimer and triggers apoptosis by binding to its cognate receptor Fas (CD95), forming the Fas-FasL death-inducing signaling complex (DISC). This activation leads to the recruitment of adaptor proteins (FADD) and initiator caspases (caspase-8), ultimately activating executioner caspases (caspase-3, -6, -7) that cleave cellular substrates and lead to cell death.
Beyond apoptosis, FasL signaling can also:
- Induce necroptosis (programmed necrosis) under certain conditions
- Trigger inflammatory responses through NF-κB activation
- Promote IL-1β release from glial cells
- Modulate synaptic plasticity and neuronal excitability
FasL is expressed in various tissues with notable patterns relevant to neurodegeneration:
- Brain: Expressed in neurons, astrocytes, and microglia
- Immune system: High expression in activated T lymphocytes and natural killer (NK) cells
- Testis: High expression in Sertoli cells (immune privileged site)
- Eye: Expressed in corneal and retinal cells (immune privileged sites)
In the brain, both neurons and glial cells can express FasL, creating a system for regulated cell death and immune modulation.
In Alzheimer's disease (AD), FasL plays a complex role in amyloid-beta (Aβ)-induced neurotoxicity:
- Aβ-mediated FasL upregulation: Amyloid-beta peptides upregulate FasL expression in neurons and astrocytes, creating a pro-apoptotic environment [1]
- Synaptic dysfunction: FasL signaling contributes to synaptic loss through caspase activation [2]
- Microglial activation: Aβ can induce FasL expression in microglia, promoting neuroinflammation [3]
- Tau pathology: FasL-mediated apoptosis may accelerate tau phosphorylation and spread [4]
In Parkinson's disease (PD), FasL is implicated in dopaminergic neuron loss:
- Mitochondrial dysfunction: Environmental toxins (e.g., MPTP, rotenone) upregulate FasL and trigger dopaminergic neuron apoptosis [5]
- α-Synuclein aggregation: FasL expression is elevated in PD brains and may be induced by α-synuclein oligomers [6]
- Microglial neurotoxicity: Activated microglia express FasL and can kill neurons through Fas-FasL interactions [7]
- Genetic associations: Certain FASLG polymorphisms may increase PD risk [8]
FasL contributes to motor neuron degeneration in ALS:
- SOD1 mutations: Mutant SOD1 proteins upregulate FasL in motor neurons and astrocytes [9]
- Non-cell autonomous toxicity: FasL expression in astrocytes mediates motor neuron death [10]
- TDP-43 pathology: TDP-43 aggregates are associated with increased FasL expression [11]
- Huntington's disease: FasL-mediated apoptosis contributes to striatal neuron loss [12]
- Multiple sclerosis: FasL on autoreactive T cells and microglia contributes to demyelination [13]
- Prion diseases: Prion protein aggregation induces FasL expression [14]
Targeting the Fas-FasL pathway represents a therapeutic strategy for neurodegenerative diseases:
- Fas/Fc decoy receptors: Soluble Fas-Fc can block FasL signaling
- Small molecule inhibitors: Various compounds are being developed to block DISC formation
- Neutralizing antibodies: Anti-FasL antibodies can prevent apoptosis
- Immune suppression risk: Blocking FasL globally can increase cancer risk and autoimmune reactions
- Blood-brain barrier: Therapeutic agents must penetrate the BBB
- Timing: Inhibiting apoptosis may be most effective in early disease stages
- Nanoparticle-delivered FasL inhibitors
- Gene therapy approaches using AAV vectors
- Combination therapies with other neuroprotective agents
- -844T>C polymorphism: Associated with altered FasL expression levels
- -672A>G polymorphism: May influence autoimmune disease risk
- Certain FASLG variants have been linked to increased risk of:
- Sporadic Parkinson's disease
- Multiple sclerosis
- ALS with autoimmune features
FasL interacts with several proteins relevant to neurodegeneration:
- FAS (CD95): Primary receptor mediating apoptosis
- FADD: Adaptor protein in death receptor signaling
- Caspase-8: Initiator caspase in extrinsic apoptosis
- Caspase-3: Executioner caspase
- DR5: Can also bind FasL in some contexts
- X-linked inhibitor of apoptosis (XIAP): Regulated by FasL signaling
¶ Diagnostic and Prognostic Potential
- Soluble FasL (sFasL) in cerebrospinal fluid (CSF) as a potential biomarker
- Peripheral blood FasL levels correlate with disease progression in some studies
- FasL expression as a marker for neuroinflammation
- Tracking apoptosis in animal models of neurodegeneration
Additional evidence sources: